Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 4/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27081581 | 0.79 | SCN8A (0.37) | MAP4K4GRM2SCN1ASCN8AHRH3 | |
| SCHEMBL27083119 | 0.77 | NR1H2 (0.50) | LMNA | |
| SCHEMBL3403129 | 0.76 | MAP4K4 (0.43) | MAP4K4GRM2SCN8AHRH3LTA4H | |
| SCHEMBL24192780 | 0.75 | MAP4K4 (0.45) | MAP4K4GRM2LTA4HDDR1 | |
| SCHEMBL24566587 | 0.75 | MAP4K4 (0.45) | MAP4K4GRM2LTA4HDDR1 | |
| SCHEMBL24192361 | 0.75 | MAP4K4 (0.45) | MAP4K4GRM2LTA4HDDR1 | |
| Hydrochloric Acid SCHEMBL20640298 | 0.72 | LMNA (0.62) | MAP4K4GRM2SCN1ASCN8AHRH3 | |
| SCHEMBL13460128 | 0.72 | MAP4K4 (0.41) | MAP4K4GRM2HRH3LMNALTA4H | |
| SCHEMBL13460106 | 0.72 | MAP4K4 (0.41) | MAP4K4GRM2HRH3LMNALTA4H | |
| SCHEMBL24192364 | 0.72 | MAP4K4 (0.56) | MAP4K4GRM2SCN8AHRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313972-B1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-01-29 | — | — | EP | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217967-A1 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | MAP4K4 1152/4885GRM2 396/4885SCN1A 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.